U
D

Conversation

the

11/11/11 | Uncategorized

Founding CEO Barbara Fox of Avaxia Biologics Raises $2.2M

By Lori Valigra (Correspondent, Mass High Tech)
Avaxia Biologics Inc., a Lexington-based developer of oral antibody drugs for the gastrointestinal tract, completed its first close of $2.2 million of a Series A financing led by angel investors, its CEO and founder Barbara Fox told Mass High Tech.

Of the total, $1.2 million was convertible debt, most of which came in in May, and $1 million was new funding that closed last Friday. The company is looking for $1.5 million to finish the Series A round by the end of the year, Fox said. She added that the company is in advanced discussions with several other qualified investors.

» Read the full article at Mass High Tech.

Editor

Editor

The Switch Editorial Team.

Straight to your inbox.

The best content on the future faces of tech and startups.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

SHARE THIS STORY

NEW COHORT STARTS JANUARY 2024

Join the Angel Sessions

Develop strategic relationships, build skills, and increase your deal flow through our global angel group and investing course.

RELATED ARTICLES
[yarpp]